thalidomide has been researched along with Sarcoidosis, Pulmonary in 7 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Sarcoidosis, Pulmonary: Sarcoidosis affecting predominantly the lungs, the site most frequently involved and most commonly causing morbidity and mortality in sarcoidosis. Pulmonary sarcoidosis is characterized by sharply circumscribed granulomas in the alveolar, bronchial, and vascular walls, composed of tightly packed cells derived from the mononuclear phagocyte system. The clinical symptoms when present are dyspnea upon exertion, nonproductive cough, and wheezing. (Cecil Textbook of Medicine, 19th ed, p431)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Limited data report thalidomide improves cutaneous sarcoidosis; no benefit has been reported for pulmonary localization." | 9.16 | Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids. ( Antonelli, A; Barachini, P; Calabrese, R; Carpi, A; Cei, G; Cristofani, R; Fazzi, P; Manni, E; Piazza, S; Siciliano, G, 2012) |
| "To determine the benefit and corticosteroid-sparing potential of thalidomide in corticosteroid-dependent pulmonary sarcoidosis." | 9.12 | The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. ( Byars, T; Cox, CE; Hartung, C; Judson, MA; Silvestri, J, 2006) |
| "We present the case of a 71-year-old woman with a long-standing history of refractory pulmonary sarcoidosis, who, upon commencement of treatment with lenalidomide for her newly diagnosed 5q-myelodysplastic syndrome, showed a remarkable, immediate, unexpected response and recovery of her sarcoidosis-related symptoms, improvement of her vital capacity, and complete clearance of her bibasal alveolor infiltrates." | 7.81 | Use of Lenalidomide in 5q-Myelodysplastic Syndrome Provides Novel Treatment Prospects in Management of Pulmonary Sarcoidosis. ( Bazargan, A; Giv, MJ; Yoosuff, A, 2015) |
| " Because administration of low doses of thalidomide has been successful in treating other inflammatory diseases, it was used in a patient with systemic sarcoidosis who was unresponsive to corticosteroids and in a patient with pulmonary sarcoidosis, in whom Kaposi's sarcoma developed after a course of corticosteroid therapy." | 7.69 | Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. ( Bonaccorsi, P; Calvieri, S; Carlesimo, M; Giustini, S; Rossi, A, 1995) |
| "Limited data report thalidomide improves cutaneous sarcoidosis; no benefit has been reported for pulmonary localization." | 5.16 | Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids. ( Antonelli, A; Barachini, P; Calabrese, R; Carpi, A; Cei, G; Cristofani, R; Fazzi, P; Manni, E; Piazza, S; Siciliano, G, 2012) |
| "To determine the benefit and corticosteroid-sparing potential of thalidomide in corticosteroid-dependent pulmonary sarcoidosis." | 5.12 | The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. ( Byars, T; Cox, CE; Hartung, C; Judson, MA; Silvestri, J, 2006) |
| "We present the case of a 71-year-old woman with a long-standing history of refractory pulmonary sarcoidosis, who, upon commencement of treatment with lenalidomide for her newly diagnosed 5q-myelodysplastic syndrome, showed a remarkable, immediate, unexpected response and recovery of her sarcoidosis-related symptoms, improvement of her vital capacity, and complete clearance of her bibasal alveolor infiltrates." | 3.81 | Use of Lenalidomide in 5q-Myelodysplastic Syndrome Provides Novel Treatment Prospects in Management of Pulmonary Sarcoidosis. ( Bazargan, A; Giv, MJ; Yoosuff, A, 2015) |
| " Because administration of low doses of thalidomide has been successful in treating other inflammatory diseases, it was used in a patient with systemic sarcoidosis who was unresponsive to corticosteroids and in a patient with pulmonary sarcoidosis, in whom Kaposi's sarcoma developed after a course of corticosteroid therapy." | 3.69 | Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. ( Bonaccorsi, P; Calvieri, S; Carlesimo, M; Giustini, S; Rossi, A, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giv, MJ | 2 |
| Yoosuff, A | 1 |
| Bazargan, A | 2 |
| Sahu, KK | 1 |
| Varma, SC | 1 |
| Bargagli, E | 1 |
| Olivieri, C | 1 |
| Rottoli, P | 1 |
| Fazzi, P | 1 |
| Manni, E | 1 |
| Cristofani, R | 1 |
| Cei, G | 1 |
| Piazza, S | 1 |
| Calabrese, R | 1 |
| Antonelli, A | 1 |
| Siciliano, G | 1 |
| Barachini, P | 1 |
| Carpi, A | 1 |
| Judson, MA | 1 |
| Silvestri, J | 1 |
| Hartung, C | 1 |
| Byars, T | 1 |
| Cox, CE | 1 |
| Carlesimo, M | 1 |
| Giustini, S | 1 |
| Rossi, A | 1 |
| Bonaccorsi, P | 1 |
| Calvieri, S | 1 |
1 review available for thalidomide and Sarcoidosis, Pulmonary
| Article | Year |
|---|---|
Cytokine modulators in the treatment of sarcoidosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; C | 2011 |
2 trials available for thalidomide and Sarcoidosis, Pulmonary
| Article | Year |
|---|---|
Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids.
Topics: Adult; Aged; Contraindications; Dose-Response Relationship, Drug; Drug Resistance; Feasibility Studi | 2012 |
The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis.
Topics: Adrenal Cortex Hormones; Black or African American; Drug Therapy, Combination; Female; Humans; Hydro | 2006 |
4 other studies available for thalidomide and Sarcoidosis, Pulmonary
| Article | Year |
|---|---|
Use of Lenalidomide in 5q-Myelodysplastic Syndrome Provides Novel Treatment Prospects in Management of Pulmonary Sarcoidosis.
Topics: Aged; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Immunolog | 2015 |
Lenalidomide in Nonmalignant Disorders: A New Ray of Hope for Refractory Sarcoidosis.
Topics: Anemia, Macrocytic; Female; Humans; Immunologic Factors; Lung; Radiography; Sarcoidosis, Pulmonary; | 2015 |
Response.
Topics: Anemia, Macrocytic; Female; Humans; Immunologic Factors; Lung; Radiography; Sarcoidosis, Pulmonary; | 2015 |
Treatment of cutaneous and pulmonary sarcoidosis with thalidomide.
Topics: Aged; Female; Humans; Middle Aged; Sarcoidosis; Sarcoidosis, Pulmonary; Sarcoma, Kaposi; Skin Diseas | 1995 |